40
Written in Blood
“This study indicates that non–
ruxolitinib-treated primary myelofibrosis
patients younger than 65 years of age at
diagnosis with [DIPSS] intermediate-2
or high-risk disease are likely to benefit
from HCT,” Dr. Kröger and co-authors
wrote. “For patients with low-risk
disease, non-transplant approaches may
be appropriate.” Individual counseling is
indicated for lower-risk patients.
However, the authors did note
some caveats to their findings. Patients
Results of Patients with Primary Myelofibrosis Receiving AlloSCT (Data at the Time
of Transplant) or Nonexperimental Conventional Therapy (Data at the Time of Diagnosis)1
TABLE 3.
Allogeneic SCT
Conventional Therapy
Survival proportion
(95% CI)
Year 1
Year 5
Year 10
Year 1
Year 5
Year 10
Low risk
100%
69% (48-99)